MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo by D. Torella et al.
Antonio Curcio, Gianluigi Condorelli and Ciro Indolfi
Leone, Cheryl D. Waring, Angela Bochicchio, Carla Vicinanza, Iolanda Aquila, 
Daniele Torella, Claudio Iaconetti, Daniele Catalucci, Georgina M. Ellison, Angelo
Vitro and Vascular Remodeling In Vivo
MicroRNA-133 Controls Vascular Smooth Muscle Cell Phenotypic Switch In
ISSN: 1524-4571 
Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 0009-7330. Online
TX 72514
Circulation Research is published by the American Heart Association. 7272 Greenville Avenue, Dallas,
doi: 10.1161/CIRCRESAHA.111.240150
2011, 109:880-893: originally published online August 18, 2011Circulation Research 
http://circres.ahajournals.org/content/109/8/880
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
http://circres.ahajournals.org/content/suppl/2011/08/18/CIRCRESAHA.111.240150.DC1.html
Data Supplement (unedited) at: 
http://www.lww.com/reprints




Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
http://circres.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Circulation Research is online at 
 at UNIV OF CALIFORNIA SAN DIEGO on September 30, 2011http://circres.ahajournals.org/Downloaded from 
Integrative Physiology
MicroRNA-133 Controls Vascular Smooth Muscle Cell
Phenotypic Switch In Vitro and Vascular Remodeling
In Vivo
Daniele Torella, Claudio Iaconetti, Daniele Catalucci, Georgina M. Ellison, Angelo Leone,
Cheryl D. Waring, Angela Bochicchio, Carla Vicinanza, Iolanda Aquila, Antonio Curcio,
Gianluigi Condorelli, Ciro Indolfi
Rationale: MicroRNA (miR)-1 and -133 play a crucial role in skeletal and cardiac muscle biology and
pathophysiology. However, their expression and regulation in vascular cell physiology and disease is
currently unknown.
Objective: The aim of the present study was to evaluate the role, if any, of miR-1 and miR-133 in vascular smooth
muscle cell (VSMC) phenotypic switch in vitro and in vivo.
Methods and Results: We demonstrate here that miR-133 is robustly expressed in vascular smooth muscle cells
(VSMCs) in vitro and in vivo, whereas miR-1 vascular levels are negligible. miR-133 has a potent inhibitory role
on VSMC phenotypic switch in vitro and in vivo, whereas miR-1 does not have any relevant effect per se. miR-133
expression is regulated by extracellular signal–regulated kinase 1/2 activation and is inversely correlated with
VSMC growth. Indeed, miR-133 decreases when VSMCs are primed to proliferate in vitro and following
vascular injury in vivo, whereas it increases when VSMCs are coaxed back to quiescence in vitro and in vivo.
miR-133 loss- and gain-of-function experiments show that miR-133 plays a mechanistic role in VSMC growth.
Accordingly, adeno-miR-133 reduces but anti-miR-133 exacerbates VSMC proliferation and migration in vitro
and in vivo. miR-133 specifically suppresses the transcription factor Sp-1 expression in vitro and in vivo and
through Sp-1 repression regulates smooth muscle gene expression.
Conclusions: Our data show that miR-133 is a key regulator of vascular smooth muscle cell phenotypic switch
in vitro and in vivo, suggesting its potential therapeutic application for vascular diseases. (Circ Res. 2011;
109:880-893.)
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 vascular remodeling
Vascular smooth muscle cells (VSMCs) within adultblood vessels proliferate at a very low rate, exhibit very
low synthetic activity, and express a unique repertoire of
contractile proteins, ion channels, and signaling molecules.1
Unlike skeletal muscle and cardiac muscle, which consist of
terminally differentiated cells, adult VSMCs retain remark-
able plasticity and can undergo rather profound and reversible
changes in phenotype and growth properties in response to
changes in local environmental cues. Salient examples of
VSMC plasticity can be seen in response to vascular injury
when VSMCs dramatically increase their proliferation, mi-
gration, and synthetic capacity, playing a critical role in
vascular repair.1,2 A detrimental consequence of the high
degree of plasticity exhibited by adult VSMCs is that it can
lead to an adverse phenotypic switch and acquisition of
characteristics that can contribute to development or progres-
sion of vascular disease in humans, including atherosclerosis,
restenosis, cancer, and hypertension.1–3
VSMC phenotypic modulation is characterized by signifi-
cant changes in gene expression patterns, matrix and cytokine
production, contractility, and growth state, ultimately leading
to their switch from a synthetic to a proliferative phenotype.
Original received January 3, 2011; revision received August 8, 2011; accepted August 9, 2011. In July 2011, the average time from submission to first
decision for all original research papers submitted to Circulation Research was 13.5 days.
From the Laboratory of Molecular and Cellular Cardiology, Cardiovascular Institute (D.T., C. Iaconetti, G.M.E., A.L., A.B., C.V., I.A., A.C., C.
Indolfi), Magna Graecia University, Catanzaro, Italy; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University (D.T.,
G.M.E., C.D.W.), Liverpool, United Kingdom; Istituto di Ricovero e Cura a Carattere Scientifico Multimedica (D.C., G.C.), Milan, Italy; (G.C.), Istituto
di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (D.C., G.C.), Segrate, Milan, Italy.
Drs Torella and Iaconetti contributed equally to this work.
Correspondence to Daniele Torella, MD, PhD, Cardiovascular Institute, Laboratory of Molecular and Cellular Cardiology, Department of Experimental
and Clinical Medicine, Magna Graecia University, Campus S. Venuta, Viale Europa, Germaneto, 88100 Catanzaro, Italy (E-mail dtorella@unicz.it); or
Ciro Indolfi, MD, Cardiovascular Institute, Laboratory of Molecular and Cellular Cardiology, Department of Experimental and Clinical Medicine, Magna
Graecia University, Campus S. Venuta, Viale Europa, Germaneto, 88100 Catanzaro, Italy (E-mail indolfi@unicz.it)
© 2011 American Heart Association, Inc.
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.111.240150
880 at UNIV OF CALIFORNIA SAN DIEGO on September 30, 2011http://circres.ahajournals.org/Downloaded from 
Thus, understanding the regulatory mechanisms underlying
the VSMC phenotypic switch is of paramount importance.1–3
One of the key breakthroughs for the study of gene
expression regulation has recently been the discovery of
microRNAs (miRNAs or miRs) and their role in gene
silencing through mRNA degradation or translational inhibi-
tion.4,5 Increasing evidence indicates that miRNAs regulate
key genetic programs in cardiovascular biology, physiology,
and disease.4,5 In particular, miR-21, -143, -145, -221, -222
have all been implicated to play a role in VSMC function and
phenotypic plasticity.6–11
More recently, 2 articles demonstrated that miR-1 is
induced by myocardin overexpression in human SMCs,
contributing to myocardin-dependent reduction of human
SMC growth in vitro.12,13 miR-133a-1/miR-1-2 and miR-
133a-2/miR-1-1 are 2 bicistronic miRNA clusters reported to
be specifically expressed in cardiac and skeletal muscle.4,5 A
third bicistronic miRNA cluster, comprising miR-206 and
miR-133b, is expressed specifically in skeletal muscle but not
in the heart.4,5 miR-1 (miR-1-1/miR-1-2) and miR-133 (miR-
133a-1/miR-133a-2) play essential roles in cardiac and skel-
etal muscle development, physiology, and disease4,5; how-
ever, their functions in VSMCs and vascular disease are
largely unknown. Thus, the aim of the present study was to
evaluate the role, if any, of miR-1 and miR-133 in VSMC
phenotypic switch in vitro and in response to vascular injury
in rat carotid arteries in vivo.
Methods
Adenoviruses expressing miR-1 (adeno-miR-1) and miR-133
(adeno-miR-133) were obtained as previously described.14 Anti-miR
constructs were obtained from Ambion (Austin, TX). Balloon injury
of the right carotid artery was performed in male Wistar rats using
a Fogarty 2F arterial embolectomy catheter as described.15,16
miR-133 probe for FISH analysis and the PBS-formulated locked-
nucleic-acid-modified anti-miR-133 were obtained from Exiqon
(Woburn, MA).
An expanded Methods section is available in the online-only Data
Supplement at http://circres.ahajournals.org.
Results
miR-1 and miR-133 Regulation in Quiescent and
Proliferating VSMCs
miR-1 and miR-133 are significantly more expressed in
skeletal and cardiac muscle tissue, compared with aorta,
carotid artery, and bronchial SM tissue (Figure 1A to 1C).
However, miR-1 was almost absent in vascular SM tissue,
whereas miR-133 was expressed at levels comparable to
those of some vascular enriched miRs, such as miR-221 and
miR-222, but lower than those of other vascular miRs, such
as miR-143 and miR-145 (Figure 1D). FISH analysis dem-
onstrated that in carotid arteries miR-133 is specifically
expressed in VSMCs (Figure 1E and Online Figure I). The
latter was confirmed at the single-cell level analyzing freshly
isolated adult aortic VSMCs (Figure 1E). miR-133a is mainly
expressed in VSMC cytoplasm, whereas miR-133b is not
expressed in VSMCs (Online Figure II).
In serum-starved synchronized quiescent adult rat aortic
VSMCs (0.50.5% BrdUpos), miR-133 was significantly
more abundant than miR-1, whereas the latter had indeed
almost negligible levels (Figure 1F). At the different time
points after serum stimulation, miR-1 levels remained un-
changed. On the other hand, miR-133 was significantly
downregulated in proliferating VSMCs (74.57.5% and
88.58.5% BrdUpos at 24 and 48 hours, respectively), com-
pared with their quiescent counterparts (Figure 1F). Cycling
VSMCs had very low levels of miR-133 as analyzed by FISH
(Figure 1G). When proliferating VSMCs were coaxed back
into quiescence by serum starvation at 48 hours for a further
48 hours (total 96 hours, 3.52.5% BrdUpos), mi-R133
transcripts increased back to levels comparable to those of
the quiescent state of the baseline experiment at time 0
(Figure 1F).
In cardiac and skeletal muscle cells, miR-133 is regulated
by several factors, including the MAPKs.17 The ras/MAPK
pathway has a crucial role in promoting VSMC proliferation
in vitro and in vivo.1,2,18 In agreement with previous find-
ings,18 PD98059, a selective inhibitor of MAPK/ERK1/2
kinase, abolished ERK1/2 phosphorylation and VSMC pro-
liferation on PDGF treatment (data not shown). More impor-
tantly, PD98059 treatment (50 mol/L) significantly inhib-
ited the PDGF-mediated downregulation of miR-133 in
proliferating VSMCs (Figure 1H). On the contrary, the
inhibition of MAPK/c-Jun N-terminal kinase with SP600125,
MAPK/p38 with SB203580, or phosphatidylinositol 3-OH
kinase with LY294002 had no significant effect on the
downregulation of miR-133 by PDGF (data not shown).
These data show that miR-133, unlike miR-1, is apprecia-
bly expressed in vascular SM tissues and cells. Importantly,
miR-133 levels show physiological variation during the
VSMC cycle by which miR-133 is downregulated in prolif-
erating VSMCs in vitro. Furthermore, ERK1/2 activation is at
least in part responsible for miR-133 downregulation when
VSMCs are primed for the phenotypic switch in vitro.
miR-133 but Not miR-1 Modulates VSMC
Proliferation In Vitro
For miR-133 or miR-1 gain-of-function experiments, VSMC
were transfected with adeno-miR-133 or adeno-miR-1.14
Non-standard Abbreviations and Acronyms
BrdU bromodeoxyuridine
CTRL controls
ERK extracellular signal–regulated kinase
FISH fluorescence in situ hybridization
GFP green fluorescent protein
MAPK mitogen-activated protein kinase
miR microRNA
MOI multiplicity of infection
PDGF platelet-derived growth factor
SM smooth muscle
SMC smooth muscle cell
SRF serum response factor
VSMC vascular smooth muscle cell
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Figure 1. miR-1 and miR-133 expression and regulation in quiescent and proliferating vascular smooth muscle cells. A and B,
miR-1 and miR-133 levels in adult rat vascular smooth muscle tissues.*P0.05 vs heart and skeletal (Sk) muscle. C, Representative
quantitative reverse transcription–polymerase chain reaction (qRT-PCR) gel of miR-1 and miR-133 expression. D, miR expression in rat
carotid artery. *P0.05 vs miR-143, and -145; #P0.05 vs miR-143, -145, -221, -222, and -133. E, miR-133 expression in rat carotid
artery (a) and isolated adult rat aortic VSMCs (b and c) (miR-133 FISH probe, green fluorescence; -smooth muscle actin (SMA), red;
4,6-diamidino-2-phenylindole [DAPI], nuclei stain, blue). Scale bars50 m (a and b), 20 m (c). F, miR-1 and miR-133 levels at 48
hours of starvation (T0h), 24 and 48 hours (T24h and T48h) during active proliferation following 10% FBS stimulation, and 48 hours fol-
lowing further serum starvation (T96h). *P0.05 vs miR-1; #P0.05 vs T0 and T96 hours. G, miR-133 downregulation in dividing
VSMCs as compared with quiescent VSMC in E (c). Scale bar20 m. H, PD98059 prevents PDGF-BB-induced miR-133 downregula-
tion. *P0.05 vs saline; #P0.05 vs PDGF.
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Figure 2. Effects of miR-1 or miR-133 gain and loss of function on VSMC proliferation in vitro. A, miR-133 overexpression by
adenoviral vector transfection (Ad-miR-133). B and C, Ad-miR-133 reduced VSMC proliferation in vitro as measured by cell counts, as
well as BrdU incorporation. B, *P0.05 vs control (CTRL) and Ad-GFP; C, *P0.05 vs BASE, †P0.05 vs CTRL and Ad-empty (24
hours). CTRL refers to untransfected cells. D, Ad-miR-133 increases miR-133 levels in a dose-dependent manner. *P0.05 vs CTRL;
#P0.05 vs 5, 50, and 100 MOI; †P0.05 vs 5, 10, and 100 MOI; ‡P0.05 vs 5, 10, and 50 MOI. E and F, Ad-miR-133 inhibits VSMC
proliferation in a dose-dependent manner. *P0.05 vs base; #P0.05 vs 5, 50, and 100 MOI; †P0.05 vs 5, 10, and 100 MOI;
‡P0.05 vs 5, 10, and 50 MOI. BASE refers to cell plates of the different groups at baseline before 10% serum stimulation (no signifi-
cant difference between groups at baseline, so they were pooled and are presented together in 1 bar). G, Differential effects of 10%
and 2% FBS media in the presence of PBS (CTRL), scrambled (Sc) anti-miR or anti-miR-133 on miR-133 expression in VSMCs in vitro.
*P0.05 vs time 0 (base); #P0.05 vs CTRL and Sc-anti-miR (10% FBS); †P0.05 vs CTRL and Sc-anti-miR (2% FBS). H and I, Anti-
miR-133 increased 2% FBS-stimulated VSMC proliferation. H, *P0.05 vs base; †P0.05 vs CTRL and anti-miR-1. I, *P0.05 vs CTRL
and anti-miR-1. J and K, Ad-miR-1 did not affect VSMC proliferation in vitro. K, *P0.05 vs BASE.
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Control cells were transfected with adeno-GFP or adeno-
empty vectors. The 2 latter adenovectors had no effect per se
on VSMC molecular phenotype or growth status compared
with naive untransfected control cells, and to simplify the
presentation, CTRL label (primarily referring to untrans-
fected control cells) includes these 3 group of controls if not
otherwise specified. For loss-of-function experiments, we
used chemically modified single stranded nucleic acids de-
signed to specifically bind to and inhibit endogenous miR-
133 (anti-miR-133) or miR-1 (anti-miR-1). A random se-
quence anti-miR molecule (scrambled anti-miR) served as
negative control.
Forty-eight hours after successful adenoviral transfection
at 50 MOI (Figure 2A and Online Figure III), VSMCs were
stimulated to proliferate by 10% FBS. miR-133 overexpres-
sion significantly reduced VSMC proliferation compared
with CTRL cells (Figure 2B and 2C). Importantly, adeno-
miR-133 reduces VSMC proliferation at different levels of
expression obtained by 10 to 100 MOIs (Figure 2D to 2F).
Anti-miR-133 administration did not affect VSMC prolif-
eration stimulated by 10% FBS (Online Figure IV). The latter
could be related to the extreme reduction of endogenous
miR-133 levels in 10% FBS stimulated VSMCs (Figure 2G),
which cannot be further affected by an additional exogenous
Figure 3. Targets of miR-133 in VSMC activation in vitro. A, Ad-miR-133 decreases and anti-miR-133 increases Sp-1 mRNA
levels in VSMCs in vitro. *P0.05 vs control (CTRL), adeno-empty, scrambled (Scramb)-anti-miR, and anti-miR-133; #P0.05 vs
CTRL, adeno-empty, adeno-miR-133, and Scramb-anti-miR. B and C, Ad-miR-133 decreases and anti-miR-133 increases Sp-1
protein levels in VSMCs in vitro. C, Optical density (OD). *P0.05 vs CTRL and anti-miR-133; #P0.05 vs CTRL and adeno-miR-
133. D, Luciferase assay of wild-type (WT) and mutant (Mut) Sp-1 3 untranslated region (UTR) in pre-miR-133- and anti-miR-133-
treated VSMCs. *P0.05 vs the respective Mut3 UTR; #P0.05 vs Scramb-miRNA, Scramb-anti-miR, and anti-miR-133; †P0.05
vs Scramb-miRNA, Scramb-anti-miR, miR-133. E, Ad-miR-133 decreases and anti-miR-133 increases moesin mRNA levels in
VSMCs in vitro. *P0.05 vs CTRL, adeno-empty, Scramb-anti-miR, and anti-miR-133; #P0.05 vs CTRL, adeno-empty, adeno-
miR-133 and Scramb-anti-miR. F and G, Ad-miR-133 decreases and anti-miR-133 increases moesin protein levels in VSMCs in
vitro. G, *P0.05 vs CTRL and anti-miR-133; #P0.05 vs CTRL and adeno-miR-133. H, Luciferase activity assay for moesin 3
UTR. *, #, †P0.05 as in D. I, Sp-1 overexpression by Sp-1mut construct transfection. *P0.05 vs GFP plasmid construct. J,
Sp-1mut overexpression effects on PDGF-BB-induced VSMC proliferation in the presence or absence of pre-miR-133. Pre-miR-
scramb indicates scrambled pre-miR. *P0.05 vs time 0 (T0); #P0.05 vs GFP, pre-miR-scramb, pre-miR-133, pre-miR-
133GFP, and pre-miR-133Sp-1mut; †P0.05 vs GFP, Sp-1mut, pre-miR-scramb, and pre-miR-133Sp-1mut. K, Ad-miR-133
decreases and anti-miR-133 increases VSMC migration in vitro. *P0.05 vs CTRL, adeno-GFP, Scramb-anti-miR, and anti-miR-
133; #P0.05 vs CTRL, adeno-GFP, adeno-miR-133, and Scramb-anti-miR.
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inhibition. Indeed, 2% FBS stimulation downregulates miR-
133 significantly less than 10% FBS (Figure 2G). Remark-
ably, in the latter conditions, anti-miR-133 treatment signif-
icantly increased VSMC proliferation compared with CTRL
cells (Figure 2H and 2I).
miR-1 overexpression, as well as that of anti-miR-1, did
not affect VSMC proliferation in vitro (Figure 2I, 2J and 2K).
In summary, miR-133, but not miR-1, plays a significant
physiological role on VSMC growth in vitro. Preventing
miR-133 downregulation on proliferative switch by miR-133
overexpression reduces VSMC proliferation. On the other
hand, knocking down miR-133 function increases VSMC
proliferation.
Targets of miR-133 in VSMC Activation In Vitro
Searching for evolutionarily conserved targets of miR-133 by
TargetScan prediction algorithms,19 we spotted the transcrip-
tion factor Sp-1, which regulates VSMC phenotypic switch in
vitro and is upregulated in animal models of vascular in-
jury,20–22 and the actin-binding protein moesin, which regu-
lates VSMC migration in vitro and in vivo.23
Adeno-miR-133 caused mRNA degradation of both Sp-1
and moesin, whereas mRNA levels of the latter 2 genes were
upregulated when VSMCs were treated with anti-miR-133
(Figure 3A and 3E). Accordingly, 2 specific luciferase
reporters for Sp-1 and moesin were specifically repressed by
exogenous miR-133 (Figure 3D and 3H). Consistent with
these findings, expression of Sp-1 and moesin proteins was
upregulated in VSMCs treated with anti-miR-133, whereas it
was decreased in VSMCs transfected with adeno-miR-133
(Figure 3B and 3C and F-G). Thus, miR-133 directly targets
for repression Sp-1 and moesin in VSMCs in vitro.
We assessed whether rescuing Sp-1 repression by miR-133
prevented miR-133 effects on VSMC proliferation. To this
end, we cotransfected VSMCs with a synthetic miR-133
mimic (pre-miR-133 precursor molecule, which, similarly to
adeno-miR-133, inhibits VSMC proliferation in vitro [Online
Figure V]) and an Sp-1 cDNA construct mutated in the 3
untranslated region binding site for miR-133 seed region
(Sp-1mut), which cannot be repressed by miR-133. Sp-1mut
overexpression (Figure 3I) directly amplified PDGF-BB-
induced VSMC proliferation in vitro (Figure 3J). More
importantly, Sp-1mut transduction rescued the inhibitory ef-
fects on VSMC proliferation in vitro by pre-miR-133 over-
expression (Figure 3J).
Finally, as moesin, as well as Sp-1, modulates VSMC
migration,1,22,23 we tested the hypothesis that miR-133 might
also inhibit cell migration. On 2% FBS stimulation for 24
hours, adeno-miR-133 transfection resulted in a significant
decrease of migrating VSMCs in the Boyden chamber.
Accordingly, anti-miR-133 did increase VSMC migration
(Figure 3K).
miR-133 Regulation of SM Genes In Vitro
SRF, which belongs to the MADS (MCMI, Agamous, Defi-
ciens, SRF) transcription factor family, is known to regulate
numerous cardiac, skeletal, and SM genes binding with the
CArG [a CC(AT)6GG motif] elements1,3 through its potent
transcriptional coactivator, myocardin.24 Importantly, SRF is
a known target for transcriptional repression by miR-1/133,
while at the same time, SRF regulates miR-1/133 transcrip-
tion.4,5 Also, the hearts of miR-133a-1/miR-133a-2 double
knockout mice are characterized by a number of upregulated
genes encoding SM-restricted proteins.19 On this premise, we
first evaluated the direct effects of miR-133 gain (adeno-miR-
133 transfection) and loss of function (anti-miR-133) on
mRNA and protein levels of 5 SM genes: calponin (CNN1),
transgelin-1 (TAGLN1), and -2 (TAGLN2), -SM actin (also
called ACTA2) and SM myosin heavy chain (MYH11 or
SM-myosin heavy chain). Accordingly, miR-133 effects on
SRF and myocardin expression levels were also evaluated.
miR-133 overexpression decreased the transcript levels of
Cnn1, Tagln2, and Acta2, but it actually increased the
transcripts of Myh11 (Figure 4A). Also, adeno-miR-133 had
no effect on Tagln1 mRNA (Figure 4A). It is worth noting
here that TAGLN2 is not an SMC-restricted gene, as it is
more broadly expressed than TAGLN1, whereas MYH11 is
the most specific gene to identify SMCs.1 These mixed
effects at the mRNA level of these SM genes by miR-133
were accompanied by a decrease or increase of the correspon-
dent protein levels (Figure 4B). Accordingly, anti-miR-133
increased mRNA and protein levels of CNN1, TAGLN2 and
ACTA2, and it decreased mRNA and protein levels of
MYH11 (Figure 4A and 4B).
Furthermore, miR-133 overexpression reduced SRF
mRNA and protein levels, whereas the opposite effects were
Figure 4. miR-133 regulation of smooth muscle genes in vitro. A and B, Effects of Ad-miR-133 and anti-miR-133 on mRNA (A)
and protein (B) levels of calponin (CNN1), transgelin (TAGLN1), transgelin-2 (TAGLN2), -smooth muscle actin (ACTA2), and
smooth muscle myosin heavy chain (MYH11). *P0.05 vs CTRL; #P0.05 vs Ad-miR-133. On the right of B, representative West-
ern blot of the 5 smooth muscle protein levels in adeno-empty, adeno-miR-133, scrambled anti-miR (Scramb- or Sc-anti-miR), or
anti-miR-133-transfected VSMCs. C, Effects of Ad-miR-133 and anti-miR-133 on SRF mRNA levels. *P0.05 vs control (CTRL),
Ad-empty, Scramb-anti-miR, and anti-miR-133; #P0.05 vs CTRL, Ad-empty, Scramb-anti-miR, and adeno-miR-133. D, Optical
density (OD) of SRF protein levels measured by Western blots as representatively shown on the right. *,#P0.05 as in C. E,
Effects of Ad-miR-133 and anti-miR-133 on myocardin mRNA levels; Pnot significant. F, miR-133 levels on PDGF treatment in
VSMCs. *P0.05 vs 0 and 3 hours. G, Ad-miR-133 reduced PDGF-induced VSMC proliferation in vitro. *P0.05 vs BASE;
†P0.05 vs CTRL and Ad-GFP 24 hours. H, Ad-miR-133 prevented PDGF-induced smooth muscle gene downregulation in vitro.
*P0.05 vs no PDGF treatment (none, open bars); #P0.05 vs relative Ad-empty. I, Pre-miR-133 effects on Sp-1, Klf4, and myo-
cardin mRNA levels in PDGF-BB-stimulated proliferating VSMCs; *P0.05 vs no PDGF treatment; #P0.05 vs relative pre-miR-
scrambled. J, Sp-1mut and pre-miR-133 overexpression effects on the modulation of Klf-4 and Myocardin levels in proliferating
PDGF-BB-stimulated VSMCs in vitro. *P0.05 vs GFP,pre-miR-scramb,pre-miR-133,pre-miR-133GFP,pre-miR-133Sp-1mut;
#P0.05 vs GFP,Sp-1mut, pre-miR-scramb, and pre-miR-133Sp-1mut. K, Sp-1mut and pre-miR-133 overexpression effects on the
modulation of MYH11 and ACTA2 levels in proliferating VSMCs in vitro. *,#P0.05 as in J.
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fostered by the anti-miR-133 (Figure 4C and 4D). Finally,
miR-133 does not directly regulate myocardin expression in
rat VSMCs in vitro (Figure 4E).
An established model for VSMC phenotypic modulation in
vitro involves treatment of VSMCs with PDGF-BB to induce
SM gene downregulation and cell proliferation.25 PDGF-BB
is known to increase Sp-1 expression and activity, promoting
its phosphorylation and nuclear localization.22,25 PDGF-BB-
activated Sp-1 in turn increases the activity of KLF4 to
repress myocardin, toggling SRF from the differentiation to
the proliferative program of VSMCs.22 As the differential
effects of miR-133 on its own on SM genes and their
transcriptional activators and coactivators may also be depen-
dent on the culture in vitro conditions, we tested their
interplay in adult rat aortic VSMCs treated with PDGF-BB,
which is a proper stimulus to evaluate VSMC phenotypic
switch in vitro.
PDGF-BB downregulated miR-133 expression (Figure 4F)
and reduced the expression of Tagln1, Acta2, and Mhy11,
inducing VSMC proliferation (Figure 4G and 4H). Impor-
tantly, adeno-miR-133 prevented PDGF-BB-induced Tagln1,
Acta2, and Myh11 downregulation, reducing PDGF-BB-
dependent VSMC proliferation (Figure 4G and 4H). Also
remarkably, miR-133 overexpression prevented PDGF-BB-
induced Sp-1 and Klf4 upregulation and myocardin down-
regulation (Figure 4I). When Sp-1mut was overexpressed in
VSMCs, miR-133 was unable to prevent PDGF-BB-
dependent Klf-4 upregulation, as well as myocardin, Myh11,
and Acta2 downregulation, in proliferating VSMCs in vitro
(Figure 4J and 4K).
These data point to miR-133 preventing VSMC phenotypic
switch in vitro by specifically repressing Sp-1 expression.
Adeno-miR-133 Transfection in the Rat Carotid
Artery Reduces VSMC Phenotypic Switch and
Proliferation After Balloon Injury In Vivo
After balloon injury in rats, VSMC activation in the vascular
media layer reaches its peak at 2 days.15–16 At this time point,
miR-133 levels were barely detectable in VSMCs of the
media layer of injured arteries compared with the uninjured
counterparts when evaluated by both quantitative reverse
transcription–polymerase chain reaction and FISH (Figure
5A and 5B). miR-133 began to increase in the media layer at
7 days after injury, when it was still absent in neointimal
VSMCs (Figure 5A and 5B). Finally, at 14 days, miR-133
was expressed in both medial and neointimal VSMCs (Figure
5A and 5B). On the other hand, miR-1 levels remained
unchanged in response to injury (Figure 5A).
Adeno-miR-133 or adeno-miR-1 were intraartery infused,
as previously described.8,11 Carotid arteries of control rats
were transfected with either an adeno-GFP, an adeno-empty,
or just saline (labeled as CTRL unless otherwise specifically
stated). Adeno-miR-133 transfection increased vascular miR-
133 levels 48 hours following balloon injury compared with
CTRL. Indeed, adeno-miR-133 normalized miR-133 expres-
sion in injured arteries to levels, similar to normal uninjured
vessels (Figure 5C). Adeno-miR-1 successfully increased
miR-1 vascular expression in injured vessels (Figure 5C).
In the carotid arteries treated with transfection of adeno-
miR-133, a significantly lower ratio of Ki-67-positive nuclei
to total cells (proliferation index32%) was observed
compared with CTRL carotid vessels (proliferation in-
dex163.5%; P0.05), 2 days after balloon injury (Figure
5D and 5E). No effects on VSMC proliferation were observed
by the transfection of adeno-miR-1 (Figure 5D). Moreover,
Sp-1 and moesin were upregulated in carotid arteries follow-
ing vascular injury (Figure 5F and 5G) compared with
uninjured vessels in CTRL rats (Figure 5F and 5G). On the
other hand, Sp-1 and moesin injury-induced vascular upregu-
lation was inhibited by adeno-miR-133 treatment in agree-
ment with the destabilizing influence of miRNAs on their
specific targets (Figure 5F and 5G).
Thus, miR-133 inversely correlates with VSMC pheno-
typic switch and proliferation in injured vessels in vivo, and
its forced expression reduces VSMC activation after vascular
injury, where it negatively regulates the expression of its
specific targets, Sp-1 and moesin.
miR-133 Plays a Pivotal Role in Regulating
Neointimal Hyperplasia After Balloon Injury
In Vivo
In CTRL rats (n8), balloon injury of the carotid artery
promoted after 14 days the generation of a thick neointima,
which significantly reduced the lumen of the vessel (Figure
6A to 6C). This response was nearly abolished by adeno-
miR-133 (n7). Indeed, miR-133 overexpression signifi-
cantly reduced neointimal hyperplasia (neointimal area
0.0730.019 mm2, neointima/media ratio0.4980.137) 14
days after experimental balloon angioplasty, compared with
CTRL groups (neointimal area0.1780.023 mm2, neointi-
ma/media ratio1.2500.129) (Figure 6A and 6B). Adeno-
miR-1 (n7) had no effect on neointimal formation (neointimal
area0.1800.035 mm2, neointima/media ratio1.190
0.168) (Figure 6A and 6B). In particular, the neointimal tissue of
the injured carotid arteries was reduced by 60% in the rats
transfected with adeno-miR-133, compared with CTRL (Figure
6C). The medial layer (0.1430.014 mm2 in CTRL) was not
affected by adeno-miR-133 (0.1490.013 mm2, Pnot signif-
icant), suggesting a normal arterial contractile state. Adeno-GFP
(n6) did not affect vascular remodeling per se at 14 days after
balloon injury (neointimal area0.1790.018 mm2, neointima/
media ratio1.1870.132) (Figure 6A to 6C).
To substantiate the inhibitory role played by miR-133 on
VSMC proliferation in vivo, we evaluated the effects of
antagonizing endogenous miR-133 through the in vivo injec-
tion of a PBS-formulated locked-nucleic-acid-modified oli-
gonucleotide to specifically suppress miR-133 (anti-miR-
133).26 On the basis of the time course of miR-133 vascular
expression after balloon injury (Figure 5A), additional rats
were implanted at 7 days after balloon injury with an osmotic
pump (under the skin of the rat neck) to systemically release
anti-miR-133 (30 mg/kg) from 7 to 14 days. To obtain an in
situ time course of vascular cell proliferation within the
vessel wall after injury, BrdU was administered intraperito-
neally (30 mg/kg) 3 times every 8 hours before each rat
euthanasia to label proliferating cells. BrdU-positive VSMCs
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Figure 5. miR-133 regulation of VSMC proliferation in vivo after balloon injury. A, miR-133 and miR-1 expression in the vas-
cular wall of uninjured control artery (no injury) at baseline (0 days) at 2 through 14 days after vascular injury. As already
reported,10 miR-221 is significantly upregulated after injury. *P0.05 vs no injury (0 day); #P0.05 vs 2 days. B, In situ detection
of miR-133 expression in rat carotid arteries at 0, 2, 7, and 14 days after balloon injury. 4,6-Diamidino-2-phenylindole (DAPI)
(blue) indicates cell nuclei. Scale bars50 m. C, Endogenous miR-1 and miR-133 increase by adeno-miR-1 and adeno-miR-133
in vivo transfection. *P0.05 vs CTRL;# P0.05 vs no injury CTRL and Ad-miR-133. D, Ad-miR-133 significantly reduced VSMC
proliferation in vivo. *P0.05 vs CTRL, Ad-GFP, and Ad-miR-1. E, Net reduction of Ki67 positive (green) VSMCs (smooth muscle
actin [SMA], red) in Ad-miR-133-treated compared with control (CTRL) rats 2 days after balloon injury. Scale bars50 m. F,
Moesin and Sp-1 expression (green) in VSMCs (red) was specifically reduced by Ad-miR-133 in vivo 2 days after balloon injury
compared with CTRL. Scale bars50 m. G, Sp-1 and moesin protein levels were induced at 2 days after balloon damage (injury
CTRL) compared with uninjured control (no injury), whereas Ad-miR-133 significantly reduced their induction on injury. *P0.05 vs
no injury and Ad-miR-133.
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reached their peak at 2 days and decreased from 7 to 14 days
in the media layer, whereas they peaked at 7 days and
decreased thereafter in the neointima layer of CTRL saline-
treated animals (n4 for each time point) (Figure 7A and
7B). Anti-miR-133 systemic administration reduced vascular
levels of miR-133 at 14 days after injury compared with
CTRL (Figure 7C). Importantly, anti-miR-133 treatment
(n5) maintained BrdU-positive proliferating VSMCs,
which were significantly increased in both media and neoin-
timal layers compared with CTRL at 14 days (Figure 7B).
The prolongation of VSMC proliferation by anti-miR-133
resulted in an increased neointimal formation at 14 days after
injury (neointimal area0.2550.036 mm2, neointima/media
ratio1.7430.152) compared with untreated CTRL rats
(n7, neointimal area0.1770.021 mm2, neointima/media
ratio1.1980.132), reducing vessel lumen (Figure 7D to
7F). PBS (saline) lone infusion through the osmotic pump in
additional control animals (PBS, n6) did not affect neoin-
timal formation (neointimal area0.1690.029 mm2, neoin-
tima/media ratio1.140.143) (Figure 7D to 7F).
Discussion
This study is the first to document the presence of miR-133 in
VSMCs and to reveal essential roles of this miRNA in the
control of VSMC phenotypic switch in vitro and in vivo.
Indeed, (1) miR-133 is robustly expressed in VSMCs to
levels similar to other previously characterized vascular
miRs, whereas the expression of its cognate bicistronic gene,
miR-1, is negligible; (2) miR-133 but not miR-1 regulates
VSMC growth state by inhibiting VSMC proliferation and
migration in vitro; (3) miR-133 specifically targets for repres-
sion the transcription factor Sp-1, which mediates miR-133
inhibition of SM gene downregulation and VSMC prolifera-
tion in vitro; and (4) miR-133 is downregulated in prolifer-
ating VSMCs of carotid arteries in response to balloon injury
in rats and adenoviral overexpression of miR-133 in the
vascular wall reduces, whereas anti-miR-133 systemic treat-
ment exacerbates VSMC hyperplasia after experimental bal-
loon injury, pointing to a crucial role of miR-133 in regulat-
ing pathological vascular remodeling in vivo.
miR-143 and -145 are key players in SM differentiation
program through the enhancement of myocardin expression/
Figure 6. miR-133 overexpression in
the rat carotid artery reduces neointi-
mal hyperplasia after balloon injury. A
and B, Neointimal area and neointimal/
media (N/M) ratio 14 days after balloon
injury. *P0.05 vs all. C, Hematoxylin/
eosin staining of carotid cross-sections
14 after balloon injury from the different
group of animals included in the adeno-
miR-133 in vivo study.
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activity by silencing the transcription factors Elk4 and Klf4.7
miR-145 inhibits SM proliferation and neointima formation
after vascular injury, directly repressing KLF5, which in turn
regulates myocardin.8 Furthermore, miR-145 plays a critical
role in keeping the contractile functions of VSMCs and
vessels through its regulation of the angiotensin-converting
enzyme gene.10 Finally, miR-143/145 knockout mice present
severe structural modifications of the aorta, and accordingly,
human aortic aneurysms are characterized by a significant
reduced expression of miR-143/145, pointing to a specific
role of this miRNA in vascular diseases.9 In the present study,
we have shown that miR-133 prevents smooth muscle phe-
notypic switch through direct repression of the transcription
factor Sp-1, which is a known regulator of the Klf4/myocar-
din axis. Therefore, it highly tempting to speculate that a
miRNA network involving miR-143/145 and miR-133 might
exist to cooperatively regulate VSMC phenotypic switch in
vitro and in vivo. miR-133 promotes myoblast growth,
which suppresses differentiation,4,5 whereas it suppresses
proliferation of cardiac myocytes by repressing cyclin D2
expression.19 Here we show that miR-133 robustly de-
creases rat VSMC proliferation in vitro and following
balloon injury in vivo. Also, we have data to show that
miR-133 is able to replicate its effects in rat VSMCs also
in human coronary-derived SMCs (Online Figure VI).
Therefore, miR-133 appears to have both positive and
Figure 7. Anti-miR-133 increases VSMC proliferation and neointimal formation after balloon injury. A, BrdU-positive (green)
VSMCs (smooth muscle actin [SMA], red) in the media and neointima layer before (0 day) and at 2 through 14 days after balloon injury.
4,6-diamidino-2-phenylindole (DAPI), nuclei in blue. B, VSMC proliferation (measured as percentage of BrdUpos over total VSMCs) in
the media (solid bars) and the neointima (open bars) layers in CTRL (at 2 through 14 days) and anti-miR-133-treated rats. *P0.05 vs 2
days; #P0.05 vs 7 days; †P0.05 vs 14 days. C, Anti-miR-133 systemic administration reduced miR-133 vascular levels at 14 days
after balloon injury. *P0.05 vs untreated control (control, no pump [CTRL]) and saline-treated rats. D and E, Neointimal area and neo-
intimal/media (N/M) ratio. *P0.05 vs all. F, Representative hematoxylin/eosin stainings of carotid cross-sections 14 after balloon injury
from the different group of animals included in the anti-miR-133 in vivo study.
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negative effects on proliferation, depending on the muscle
cell type.
Bicistronic genes, such as miR-143/145 and miR-221/222,
show similar changes in expression in the vessel wall.
However, this was not the case for miR-1/miR-133, as VSMC
miR-1 expression is very weak compared with miR-133.
Accordingly, previous data show that miR-133 is downregu-
lated in the carotid artery tissue subjected to damage, whereas
miR-1 was not reported by the miRNA array as being
negligible in the arterial wall.6 However, no further analysis
was performed to identify either the cellular specificity of
miR-133 expression within the vessel wall or its function.
Importantly, a differential expression for polycistronic mature
miRNAs has already been reported for miR-21 and miR-17 to
-92.27 Another intriguing possibility is that miR-1 is actively
extruded from VSMCs in a way similar to what happens for
other miRs shuttled out of the cells through exosomes.28
Two recent articles12,13 support a molecular network
whereby miR-1 is induced by myocardin overexpression to
act as a self-limiting mechanism of myocardin in the regula-
tion of SMC contraction. Indeed, miR-1 expression reduced
the proliferation of myocardin-overexpressing human SMCs.
However, miR-1 alone only slightly reduces human SMC
growth in vitro, whereas anti-miR-1 in absence of myocardin
overexpression does not have any effect on hSMC prolifera-
tion. Finally, miR-1 expression appears to be downregulated
in the vascular wall of ligated common carotid vessels. The
data above are only in part at odds with the findings of our
present study. First, the data from Zheng group12,13 are
consistent with our findings in showing minimal if not
negligible levels of miR-1 in normal quiescent human SMCs.
Second, miR-1 effects on human SMC proliferation are
mainly secondary to myocardin overexpression.12,13 Third, in
the latter 2 studies, 2 different human SMC lines were
obtained through in vitro selection, which may have a role in
the reported findings. Finally, it should be noted that we
injured carotid vessel by balloon endothelial denudation and
media injury which is different from the mouse carotid
ligation model used by Chen et al.13 Accordingly, the reduced
expression of miR-1 in the vascular wall after carotid ligation
cannot be accounted for by specific variation within SMCs, as
it may depend on other cell types within the vessel tissue.
miRNAs mediate important gene-regulatory events by
pairing to the mRNAs of protein-coding genes to direct their
repression. Here, we showed that miR-133a suppresses the
expression of the transcription factor Sp-1 and of the actin-
binding protein moesin. In particular, for its central role in
modulating VSMC phenotypic switch in vitro and in vivo, we
have therefore focused our attention on Sp-1. Sp-1 is indeed
a transcription factor activated by phenotypic switch promot-
ing stimuli1,3 on which it specifically binds the G/C suppres-
sor cis-element located in MHY11 and TAGLN-1.1,20–22
Activated Sp-1 in turn increases the activity of Klf4, which
represses myocardin and therefore downregulates most of the
SM genes.22,25 Furthermore, Sp-1 binding to the G/C repres-
sor element drives SM-gene downregulation after vascular
injury in vivo.25 Here, we show that Sp-1 repression by
miR-133 is the dominant factor underlying miR-133 effects
on SM gene regulation and VSMC proliferation in vitro
(Figure 8). Indeed, miR-133 gain- and loss-of-function ex-
periments in unstimulated VSMCs show that this miR ro-
bustly increases MHY11 (which is the most restricted SM
gene) while mildly reducing ACTA2. Accordingly, miR-133
prevents PDGF-BB-induced downregulation of MHYC11,
ACTA2, and TAGLN1 and VSCM proliferation in vitro.
Importantly, when a mutated form of Sp-1, which cannot be
targeted for repression by miR-133, is overexpressed in
VSMCs, miR-133 loses its function of maintaining the
molecular differentiation program and the cellular quiescent
state.
A long-standing paradox in vascular biology is the double
role of SRF both on VSMC proliferation and differentia-
tion.1,3,29 Indeed, SRF regulates growth-responsive genes,
such as c-fos, but it also regulates virtually every SMC-
specific gene.1,3,29 Myocardin is the main SRF coactivator to
direct SRF to function as a positive regulator of differentia-
tion, competing with other SRF cofactors, such as Elk-1,
Klf4, and others that promote SRF to function as a regulator
of proliferation.24 miR-133 is a direct transcriptional target of
SRF.4,5 However, the genetic interaction between miR-133
and SRF constitutes a negative feedback loop in which the
upregulation of miR-133 by SRF results in increased repres-
Figure 8. Proposed miR-133-dependent regulation of VSMC
phenotypic switch. Vascular injury (through the action of
environmental local cues such as mitogen ligands, ie, PDGF-
BB) activates a molecular receptor-kinase network, including
the sequential activation of the MAPK pathway, which drives
VSMC phenotypic switch. Phosphorylation and activation of
the transcription factor Sp-1, in turn, activates Klf-4-
dependent myocardin downregulation/displacement from the
SRF complex determining the downregulation of smooth
muscle genes, like smooth muscle myosin heavy chain
(MHY11). miR-133 is inhibited by MAPK/ERK1/2 in PDGF-BB-
stimulated VSMCs. However, when miR-133 is upregulated
(or physiologically active in quiescent cells), it targets Sp-1
for repression, blocking Klf-4 expression and following myo-
cardin repression. Thus, targeting Sp-1, miR-133 inhibits
VSMC phenotypic switch, preventing MYH11 (as well as other
smooth muscle genes) downregulation and VSMC prolifera-
tion. MEK indicates MAPK kinase.
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sion of SRF.4,5 Here, we show that miR-133 reduces SRF
levels in VSMCs in vitro (Figure 8). However, SRF levels are
not crucial for SM gene regulation and VSMC prolifera-
tion.1,3,29 More importantly, miR-133 targeting Sp-1, which is
needed for Klf4 activation to downregulate myocardin,22
prevents myocardin repression and VSMC proliferation on
PDGF-BB stimulation in vitro.
Finally, the mechanisms regulating miR-133 expression in
muscle cells are only partially known. Indeed, in cardiac and
skeletal muscle cells, miR-133 is regulated by several tran-
scription factors or kinases, such as MEF2,30 myogenic
regulatory factors, MAPK/ERK1/2,17 and nuclear factor of
activated T cells.31 All of these factors are intertwined with
SRF,1,3 which, as mentioned above, regulates miR-133 ex-
pression. Accordingly, the present results suggest that
MAPK/ERK1/2 is a critical upstream signaling pathway of
miR-133 expression in VSMCs that is responsible for its
downregulation when VSMCs are primed for the phenotypic
switch in vitro.
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Novelty and Significance
What Is Known?
● Adult vascular smooth muscle cells (VSMCs) possess remarkable
plasticity and can undergo reversible changes in phenotype and
growth properties in response to changes in local environmental
cues. This phenotype switching contributes to vascular disease,
including atherosclerosis, restenosis, cancer, and hypertension.
● VSMC phenotypic switch is characterized by significant changes in
gene expression, matrix and cytokine production, and contractility
and growth state.
● MicroRNAs (miRNAs) are short (22-nucleotide), noncoding RNA
molecules with the general function of translational repression
and gene silencing.
What New Information Does This Article Contribute?
● MicroRNA-133 (miR-133, previously reported to be restricted to
cardiac and skeletal muscle) is robustly expressed in VSMCs,
whereas the expression of its cognate bicistronic gene, miR-1, is
negligible.
● miR-133 regulates VSMC phenotypic switch by inhibiting VSMC
proliferation and maintaining smooth muscle gene differentiation
program.
● Vascular overexpression of miR-133 reduces neointimal hyperplasia
after experimental balloon injury.
The understanding of the regulatory mechanisms that underlie
VSMC phenotypic switch in response to vascular injury is of
paramount importance in designing effective therapies for
vascular disease. Several miRNAs regulate key genetic pro-
grams in vascular development and disease. The bicistronic
miR-1/mir-133 gene plays a fundamental role in skeletal and
cardiac muscle biology, but its function in vascular smooth
muscle remains unknown. We show here for the first time that
miR-133 is expressed in VSMCs and that miR-133 plays an
essential role in regulating VSMC phenotypic in vitro and in vivo.
miR-133 is robustly expressed in VSMCs to levels similar to
those of other previously characterized vascular miRs; however,
the expression of its cognate bicistronic gene, miR-1, is
negligible. We found that miR-133 inhibits VSMC proliferation by
repressing the transcription factor Sp-1 and that it prevents
smooth muscle gene downregulation on mitogen stimuli. miR-
133 is downregulated in proliferating VSMCs of carotid arteries
in response to balloon injury in rats, and overexpression of
miR-133 in the vascular wall reduces neointimal hyperplasia
after experimental balloon injury. These findings point to a
crucial role of miR-133 in regulating pathological vascular
remodeling and open new avenues for the use of miR-133 in the
treatment of vasculoproliferative diseases.
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Adenovirus, cell culture, and reagents 
Adenoviruses expressing miR-1 (abbreviated as Adeno-miR-1 or Ad-miR-1) and miR-133 
(Adeno-miR-133 or Ad-miR-133) were obtained as previously described (1). Green fluorescent 
protein (GFP) adenovirus vector (Adeno-GFP) or adeno-empty was used as control reporter gene 
and control virus, respectively. GFP plasmid construct and the SP-1 cDNA construct mutated in the 
3’UTR binding site for miR-133 seed region (Sp-1mut) were obtsained from Origene. The synthetic 
miR-133 mimic (pre-miR-133 precursor molecule) and the scrambled pre-MiR were obtained from 
Ambion. Adult rat aortic vascular smooth muscle cells (2) were grown in DMEM supplemented 
with 10% fetal bovine serum (FBS, Gibco). Adenoviruses were transfected as previously reported 
(1). Efficiency of the transfection of the reporter gene adenoconstruct in vitro was evaluated by 
flow-activated cell sorting (FACS) (3). Anti-miR™ to miR-1 and miR-133 (AntimiR-1 and 
AntimiR-133, respectively) and negative control 1 (a scrambled oligonucleotide, Scrambled-
AntimiR) were obtained from Ambion (Austin, Texas). The AntimiR-1, AntimiR-133, Scrambled-
AntimiR, pre-miR-133 and Scarmbled-pre-miR were introduced into the cells by reverse 
transfection using the transfection agent siPORT™ NeoFX™ (Ambion). Cell culture media was 
changed after 8 hours to remove the transfection reagent in an attempt to avoid toxicity which may 
be caused by NeoFX™. All the in vitro experiments were performed in quadruplicate, and the data 
shown as Average ±StDev.  
 
Determination of RNA Levels by Quantitative RT-PCR 
miRNAs/ mRNAs were extracted from rat adult aortic VSMCs, aortas, carotid arteries, 
bronchial tissues hearts, and skeletal muscle isolated from male Wistar Rats. Specifically, for 
miRNA/ mRNA extraction from isolated cells, mirVana™ miRNA Isolation Kit (Ambion, Inc) was 
used while Trizol was employed for miRNA/mRNA extraction from solid tissues. Specific cDNA 
was obtained using the high-capacity cDNA Reverse transcription kit (Applied Biosystems). 
TaqMan® MicroRNA Assays (Ambion) and TaqMan® Gene Expression Assays (Ambion) or  
SYBR-GREEN (Biorad) were used to quantify miRNAs (miR-1, miR-133a, miR-133b, miR-143, 
miR-145, miR-221 and miR-222) and mRNA levels, respectively, by quantitative (q)RT-PCR. 
Finally, specific localization of mature miR-133 within VSMCs was further evaluated by separating 
cytoplasmic content from nuclei (4) 
The specific sequences of the primers used are the following: calponin, (F) 
TAGAGCTTGCAGATGGGGAGCAA – (R) TGGGAAAGCTCCAGGGATGA; alpha smooth 
muscle actin, ACTA2, (F) ATCCGATAGAACACGGCATC - (R) 
AGGCATAGAGGGACAGCACA;  smooth muscle heavy chain, SM-MHC (MYH11), (F) 
CAGTTGGACACTATGTCAGGGAAA - (R) ATGGAGACAAATGCTAATCAGCC; transgelin-
1, TAGLN-1, (F)  GCATAAGAGGGAGTTCACAGACA - (R) 
GCCTTCCCTTTCTAACTGATGATC; transgelin-2, TAGLSN-2, (F) 
GCTGGCATCCGCCGAGTG - (R) GCACCTTACCAGGGTCCAATGT; serum SRF, (F) 
CCAGCGCTGTCAGCAGTGCCAAC - (R) GCTGCTCCCAGCTTGCTGCCCTATC-3'; GAPDH, 
(F) ACCACAGTCCATGCCATCAC' - (R) TCCACCACCCTGTTGCTGTA. 
 
In vitro Cell Assays 
For cell proliferation, transfected VSMCs were serum starved (0% FBS) for 36-48 hours; 
then, normal serum medium (10% FBS) was added. BrdU (10µm/L) was added every eight hours. 
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At different time points, cells were fixed and stained to detect cell proliferation, according to the 
manufacturer’s instructions (Roche) (3). The percentage of BrdU-positive VSMCs (relative to total 
cells) was determined by counting ~1000 cells in 10 randomly chosen fields/dish. In parallel 
experiments, cell counts at time 0 (Baseline, BASE) and at 12, 24, 48 and 96 hours were obtained as 
previously described (5).  
Cell proliferation was measured by two different assays to obtain complimentary data. It is 
indeed well-documented that using this protocol, the BrdU nucleoside disappear from the media in 
a manner of minutes and do not produce continuous labeling of the cells but short pulse labeling, 
that’s why is necessary to re-spike the media at intervals shorter than the S phase of the cells under 
study to have a chance to label most of those that enter the cell cycle (6). Thus, the BrdU assay, as 
above detailed, responds to the question at a single cell level on how miR-133/miR-1 affect VSMCs 
primed to re-enter the cell cycle (within the known cell cycle period lasting less than 24-hours for 
this cell type). On the other hand, cell counts at 48 hours show the net effects of miR-133/miR-1 on 
VSMC proliferation as a whole cell population.  
VSMC migration was assayed by a modification of the Boyden’s chamber method as 
previously described (5). Rat VSMCs were placed in the upper chamber, and DMEM containing 
10% serum as general migration factor was placed in the lower chamber. At the end of the assay 
period, VSMCs that had migrated to the lower side of the filter were counted under a microscope to 
quantify VSMC migration.  
VSMC activation (proliferation and migration) is secondary to a multitude of growth factors 
and therefore we primarily set the experiments to evaluate any role of miR-133 on VSMCs primed 
to proliferate/migrate in response to 10% serum. On the other hand, to directly evaluate VSMC 
phenotypic switch in vitro, we used an experimental in vitro model of VSMC modulation, which 
entails cell stimulation by PDGF-BB, which is also a known mitogen for VSMCs directly down-
regulates main VSMC genes (7).  
 
Luciferase Reporter and Activity Assay 
A fragment of the 3' un-translated region (3'-UTR) of Sp-1 or Moesin containing the 
putative predicted miR-133 binding site was ligated into the pMiR-Reporter vector (Ambion) 3' of 
the luciferase gene. As a negative control, three mutations were introduced into the seed region of 
miR-133 binding site of the Sp-1 or Moesin sequence. Adult rat VSMCs cells were plated at 10×104 
in 24-well cell culture plates. The pMir-Reporter containing the Sp-1 or Moesin binding site for 
miR-133 were co-transfected with either pre-miR-133, a scrambled miRNA, AntimiR-133 or 
Scrambled AntimiR (Ambion) using Lipofectamine 2000. Control cells (CTRL) were treated with 
lipofectamine 2000 alone. All experiments were also co-transfected with β-galactosidase vector as a 
control for transfection efficiency and normalization. Luciferase activity was measured by One-Glo 
luciferase assay (Promega) according to manufactures instructions and as previously described (8). 
 
Western blot Analysis 
Proteins were isolated from cultured VSMCs or carotid arteries and protein levels were 
determined by SDS-PAGE and Western blot analysis as previously described (3,9). The antibodies 
used were the following: rabbit anti-Moesin (Cell Signaling), mouse anti-SP-1, mouse anti-ACTA2, 
rabbit anti-TAGLN-1, mouse TAGLN-2, mouse anti-calponin, mouse anti-SRF, goat anti-GAPDH 
(Santa Cruz Biotech) and mouse anti-MYH11 (BT-562, Biomedical Technologies). 
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Animal study design and experimental balloon injury 
The animals in this study were handled according to the animal welfare regulation of the 
Magna Graecia University of Catanzaro, and the protocol was approved by the animal use 
committee of this Institution. Balloon injury of the right carotid artery was performed in male 
Wistar rats (weighing 330±30g, Harlan Italy) using a Fogarty 2F arterial embolectomy catheter 
(Baxter Healthcare Corp.) as described (3,9). After the vascular injury, the balloon-dilated  common 
carotid arteries were randomly infused through the external carotid artery with the specific 
adenoviral constructs (10,11). The rats received the following constructs after balloon injury: 
adeno-miR-1, adeno-miR-133, adeno-empty vector alone or adeno-GFP. In additional rats,  just 
saline was infused (CTRL). Also, additional carotid arteries isolated at 2 days after balloon injury 
(n=5 for each group) were dissociated and RNA extracted for real time qRT-PCR analysis of miR-
1/-133 vascular expression in vivo (3,9).  
In the miR-133 loss of function experiments in vivo, osmotic mini-pumps (Alzet) were 
implanted under the skin of the rat neck for a 1-week continuous infusion of PBS-formulated LNA-
modified AntimiR-133 (Exiqon), or just phosphate buffered saline (PBS).  
 
Tissue Immunohistochemistry and Morphological Characteristics  
After completion of the relative in vivo studies, the rat abdominal aorta was cannulated and 
perfused with 10% buffered formalin (3,8). The isolated carotid arteries were embedded in paraffin 
and 5µm cross sections were prepared on a microtome (Leica, RM2235).  
VSMC proliferation was assessed by staining 2-day balloon injured arteries (n= 5 for each 
group) for ki67 (3,8). Ki67 was detected using a rabbit polyclonal antibody against Ki67 (1:50 
dilution; Vector Labs) overnight at 4°C. A proliferation index (PI) was defined as the number of 
Ki67 positive cell nuclei in the tunica media divided by the total number of cell nuclei. Proliferating 
and newly formed VSMCs in the media as well as neointimal layers were detected through double 
staining for BrdU and α-smooth muscle actin. BrdU was detected using an antibody against BrdU 
(1:50 dilution; Roche). Vascular smooth muscle cells were detected using an antibody against 
smooth muscle (SM) α–actin (Sigma). Sp-1 and  Moesin were respectively detected with rabbit 
polyclonal antibodies against Sp-1 (1:50 dilution; Santa Cruz) and Moesin (1:50 dilution; Cell 
Signaling) overnight at 4°C. For anatomical and morphological measurements, 14 days after 
balloon-injury, EEL (external elastic membrane), IEL (internal elastic membrane), lumen, media, 
and neointimal were measured on H&E stained cross sectional carotid artery segments using a 
computerized image analysis system. The ratios between neointima and media were calculated 
(3,9). All fluorescence images were analyzed with a Zeiss LSM 710 confocal microscope and Zen 
2009 image software. 
 
Detection of miR-133 in Vessel Sections by Fluorescence In Situ Hybridization 
Fluorescent in situ hybridizations (FISH) of miR-133 and co-immunofluorescence with the 
smooth muscle marker alpha smooth muscle actin (αSMA) were performed on 5-µm paraffin-
embedded arterial sections. Briefly, paraffin embedded tissue sections were cut using a microtome 
(Leica, RM2235) and mounted on Polysine microscope slides (Fisher Scientific) and stored at room 
temperature (RT) until FISH. Paraffin wax was removed in Xylene, sections rehydrated in a series 
of decreasing ethanol solutions and washed with PBS before fixing in 4% paraformaldehyde. To 
block endogenous peroxide activity, tissue sections were treated with 0.3% H2O2 and washed in 
PBS before acetylating in acetic anhydride/triethanolamine. Sections were then washed in 2xSSC 
and PBS before permeabilisation with Proteinase K (5µg/ml) and washes with PBS.  Probes (5’ & 
3’-DIG labelled LNA miRCURY probes; Exiqon) were denatured at 90°C before dilution in 
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hybridisation buffer (50% formamide, 0.3M NaCl, 20mM Tris-HCL, 5mM EDTA, 10mM NaPO4, 
10% Dextran sulphate, 1xDenhardt’s solution, 0.5mg/ml yeast tRNA). Tissue sections were 
hybridised with miR-133a (200nM) overnight at 21°C below the predicted Tm value of the probe. 
After post-hybridization washes in 5xSSC at RT; 50% formamide/1xSSC/0.1% Tween 20 at the 
hybridisation temperature; 0.2xSSC at RT, FISH signals were detected using an Anti-Digoxigenin 
antibody and the tyramide signal amplification system (PerkinElmer) according to the 
manufacturer's instructions. To determine co-localization of miR-133a and VSMCs, VSMCs were 
stained by immunofluorescence of smooth muscle (SM) α–actin (Sigma). Tissue sections were 
treated with DAPI and mounted in Vectashield (Vector laboratories). All fluorescence images were 
analyzed with a Zeiss LSM 710 confocal microscope and Zen 2009 image software. To determine 
the success of the procedure, other tissue sections from  the same samples were hybridised with 
either a 5’-DIG labelled U6 control probe (10nM) or a 5’ & 3’-DIG labelled scrambled sequence 
probe (200nM) to act as positive and negative controls respectively.   
 
Detection of miR-133 in isolated or cultured adult aortic VSMCs by Fluorescence In Situ 
Hybridization 
Freshly isolated aortic VSMCs were isolated and suspended in growth medium. 200 µl of a 
0.5 x 106 cell/ml suspension were directly loaded in each cytofunnel and spun down at 800rpm for 3 
minutes onto poly-lysine-coated slides using a Shandon Cytospin 4 Cytocentrifuge (Thermo). 
Slides were immediately fixed using a spray fixative (Shandon Cell-Fixx, Thermo) and then 
processed for miR-133 detection by FISH as above described.  
Adult aortic VSMCs were cultured on glass chamber slides (BD Falcon), fixed with 4% 
PFA for 20 min, and then stained as above described.  
 
Statistical Analysis 
Data was analysed using ANOVA, SPSS version 10.0 (SPSS Inc.). When an significant 
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Online Figure I 
 
Online Figure I. FISH positive and negative miR probe controls.  
(A) Nuclear localization of U6 as specifically detected by U6 probe (see insert at higher 
magnification) in the representative fluorescence in situ hybridization (FISH) analysis of control un-
injured rat common carotid artery. U6 probe, green fluorescence; alpha smooth muscle actin 
(αSMA), red fluorescence; DAPI (blue fluorescence) depicts cell nuclei. (B) As negative control of 
FISH analysis, a scramble miRNA probe (Scramb-Probe) was employed; the scramble probe could 
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ONLINE FIGURE II 
 
Online Figure II. Intracellular localization of miR133a in VSMCs and miR-133b expression in 
VSMCs in vitro.  
(A) Specific localization of mature miR-133a within VSMCs was evaluated by separating 
cytoplasmic content from nuclei as previously described (see reference 4). qRT-PCR shows that 
miR-133 is mainly expressed in the cytoplasm of VSMCs. *p<0.05 vs. all. (B) miR-133b is not 
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ONLINE FIGURE III 
 
Online Figure III. Adenovirus constructs transfection in VSMCs in vitro.  
(A) FACS analysis shows that more than 85% of rat VSMCs were efficiently transfected with the 
adenoviral vector carrying the control reporter gene for green fluorescent protein (Adeno-GFP). (B) 
Ad-miR-1 and Ad-miR-133 transfection (50 MOI) significantly increased miR-1 and miR-133 
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ONLINE FIGURE IV 
 
Online Figure IV. AntimiR-1 and AntimiR-133 effects on VSMC stimulated by 10%FBS in 
vitro. (A-B) AntimiR-1 and AntimiR-133 did not affect 10%FBS-stimulated VSMC proliferation 
measured through BrdU incorporation (administered 3 times every 8 hours in 24 hours) as well as 
cell counts. F, *p<0.05 vs. BASE. 
Note. The data in Panel A is presented at 24 hours as percentage of VSMCs labeled by BrdU. The 
latter represent cells that are within the cell cycle and/or cells that have entered at least once the 
cell cycle without taking into account the actual cell counts and cell number increase over time. 
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ONLINE FIGURE V 
Online Figure V. Pre-miR-133 overexpression and VSMC proliferation in vitro. (A) Pre-miR-
133 construct was transected at different concentrations (10 through 90 nanomolar, nM) in rat adult 
VSMCs in vitro using the transfection agent siPORT™ NeoFX™ (Ambion). As a negative control, 
a scramble pre-miR sequence was used (Scrambled pre-miR). Pre-miR-133 increases miR-133 
levels in a dose dependent manner. *p<0.05 vs. CTRL and Scrambled pre-miR; #p<0.05 vs. 10, 60 
and 90 nM; †p<0.05 vs. 10, 30 and 90 nM; ‡p<0.05 vs. 10, 30 and 60 nM. CTRL refers to un-
transfected cells, which show the endogenous physiologic levels of miR-133 to compare with the 
pre-miRs’ transfection at the different concentrations. (B) Pre-miR-133 (30nM) reduced 10%FBS-
stimulated VSMC proliferation measured through BrdU incorporation (administered 3 times every 
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ONLINE FIGURE VI 
 
Online Figure VI. Human and Rat miR-133 sequence and miR-133 effects on human vascular 
smooth muscle cell proliferation. (A) Rattus norvegicus miR-133a stem-loop sequence and homo 
sapiens (hsa) miR-133a-1 and a-2 stem-loop sequences as available at http://www.mirbase.org. (B) 
The rat and human miR-133a mature sequences are identical. (C) Ad-miR-133 reduced human 
coronary artery smooth muscle cells (hVSMCs) proliferation in vitro as measured BrdU 
incorporation. B, *p<0.05 vs. BASE; †p<0.05 vs. CTRL and Ad-Empty at 24 hours.   
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